These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38063059)

  • 21. Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.
    Diehl MC; Lee JC; Daniels SE; Tebas P; Khan AS; Giffear M; Sardesai NY; Bagarazzi ML
    Hum Vaccin Immunother; 2013 Oct; 9(10):2246-52. PubMed ID: 24051434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model.
    Shen X; Söderholm J; Lin F; Kobinger G; Bello A; Gregg DA; Broderick KE; Sardesai NY
    Vaccine; 2012 Nov; 30(48):6946-54. PubMed ID: 22406460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.
    Hutnick NA; Myles DJ; Ferraro B; Lucke C; Lin F; Yan J; Broderick KE; Khan AS; Sardesai NY; Weiner DB
    Hum Gene Ther; 2012 Sep; 23(9):943-50. PubMed ID: 22650607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical potential of electroporation for gene therapy and DNA vaccine delivery.
    Lambricht L; Lopes A; Kos S; Sersa G; Préat V; Vandermeulen G
    Expert Opin Drug Deliv; 2016; 13(2):295-310. PubMed ID: 26578324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer.
    Low L; Mander A; McCann K; Dearnaley D; Tjelle T; Mathiesen I; Stevenson F; Ottensmeier CH
    Hum Gene Ther; 2009 Nov; 20(11):1269-78. PubMed ID: 19619001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of humoral immunity of hepatitis D virus DNA vaccine generated in mice by using different dosage, gene gun immunization, and in vivo electroporation.
    Shiau YT; Huang YH; Wu JC; Tao MH; Syu W; Chang FY; Lee SD
    J Chin Med Assoc; 2006 Jan; 69(1):7-13. PubMed ID: 16447920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short noncoding DNA fragments improve the immune potency of electroporation-mediated HBV DNA vaccination.
    Peng J; Shi S; Yang Z; Ding Q; Hai W; Tang H; Yang Y; Bernstein JR; Peyda P; Xu Y
    Gene Ther; 2014 Jul; 21(7):703-8. PubMed ID: 24830435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges.
    Dupuy LC; Richards MJ; Livingston BD; Hannaman D; Schmaljohn CS
    J Immunol Res; 2018; 2018():8521060. PubMed ID: 29967804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA vaccines, electroporation and their applications in cancer treatment.
    Lee SH; Danishmalik SN; Sin JI
    Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
    De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J; Lu Y; Wise MC; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Pensiero M; Sardesai NY; Bagarazzi ML; Weiner DB; Ferrari G; Tomaras GD; Montefiori DC; Corey L; McElrath MJ;
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32437332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Spearman P; Mulligan M; Anderson EJ; Shane AL; Stephens K; Gibson T; Hartwell B; Hannaman D; Watson NL; Singh K
    Vaccine; 2016 Nov; 34(46):5571-5578. PubMed ID: 27697302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates.
    Li Z; Zhang H; Fan X; Zhang Y; Huang J; Liu Q; Tjelle TE; Mathiesen I; Kjeken R; Xiong S
    Vaccine; 2006 May; 24(21):4565-8. PubMed ID: 16154246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electroporation for therapeutic DNA vaccination in patients.
    Sällberg M; Frelin L; Ahlén G; Sällberg-Chen M
    Med Microbiol Immunol; 2015 Feb; 204(1):131-5. PubMed ID: 25535102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Wilson GJ; Rodriguez B; Li SS; Allen M; Frank I; Rudnicki E; Trahey M; Kalams S; Hannaman D; Clarke DK; Xu R; Egan M; Eldridge J; Pensiero M; Latham T; Ferrari G; Montefiori DC; Tomaras GD; De Rosa SC; Jacobson JM; Miner MD; Elizaga M;
    Vaccine; 2023 Apr; 41(16):2696-2706. PubMed ID: 36935288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.
    Bodles-Brakhop AM; Heller R; Draghia-Akli R
    Mol Ther; 2009 Apr; 17(4):585-92. PubMed ID: 19223870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electroporation-mediated intradermal delivery of DNA vaccines in nonhuman primates.
    Adam L; Le Grand R; Martinon F
    Methods Mol Biol; 2014; 1121():309-13. PubMed ID: 24510834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor therapeutic and antimetastatic activity of electroporation-delivered human papillomavirus 16 E7 DNA vaccines: a possible mechanism for enhanced tumor control.
    Lee IH; Park JB; Cheong M; Choi YS; Park D; Sin JI
    DNA Cell Biol; 2011 Dec; 30(12):975-85. PubMed ID: 21649506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.